Xadago (safinamide) / Supernus Pharma, Sun Pharma, Meiji Seika, Zambon, Newron, Eisai, Valeo Pharma 
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xadago (safinamide) / Meiji Seika, Zambon, Supernus Pharma
2017-003254-17: Safety and efficacy of Safinamide (Xadago®) in apathy associated with Parkinson's disease Seguridad y eficacia de la Safinamida (Xadago®) en la apatía asociada a la enfermedad de Parkinson

Ongoing
4
36
Europe
Film-coated tablet, Xadago
Institut de Recerca Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital de la Santa Creu i Sant Pau
Parkinson's disease Enfermedad de Parkinson, Parkinson's disease Enfermedad de Parkinson, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05312632: A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Completed
4
201
RoW
Safinamide Mesilate, Equfina, ME2125
Eisai Korea Inc.
Parkinson Disease
05/23
05/23
2018-004892-11: A randomized, double-blind, placebo controlled, multicentre study to evaluate the effect of safinamide on freezing of gait (FOG) in mid- to late-stage fluctuating PD patients Studio multicentrico randomizzato, in doppio cieco, controllato con placebo di valutazione dell’effetto della safinamide sul freezing della marcia nei pazienti con malattia di parkinson in fase medio-avanzata

Not yet recruiting
3
128
Europe
Xadago, [043906039], Tablet, XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE, XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
OSPEDALE SANTA MARIA DELLA MISERICORDIA, Zambon s.p.a.
• Subjects of both genders over 18 years of age, with a clinical diagnosis of idiopathic PD• A Modified Hoehn and Yahr stage of = 4 in the “off” state;• A stable (4 weeks since last modification) anti-parkinsonian therapy; • The presence of FOG (defined as the persistence of gait hesitation and failure in starting the gait or the reported sensation of having the legs “frozen” or “glued to the ground”) even on an optimized dopaminergic treatment (patients with FOG item 3 score >0) • Soggetti maggiorenni con Malattia di Parkinson idiopatica;• Stadio Hoehn e Yahr di = 4 nello stato "off";• Una terapia antiparkinsoniana stabile (4 settimane dopo l'ultima modifica)• La presenza di FOG (definita come la persistenza di esitazione dell'andatura e fallimento nell'avvio dell'andatura o la sensazione riportata di avere le gambe "congelate" o "incollate a terra") anche su un trattamento dopaminergico ottimizzato (pazienti con punteggio all’item 3 del FOG-Q > 0), idiopathic Parkinson's disease (H & Y: = 4 in "off"); in stable therapy with hesitation of gait and failure to start gait or the feeling of having legs "glue to the ground" M. di Parkinson idiopatica (H&Y: = 4 in "off"); in terapia stabile con esitazione dell'andatura e fallimento nell'avvio dell'andatura o la sensazione riportata di avere le gambe "incollate a terra", Diseases [C] - Nervous System Diseases [C10]
 
 
SUCCESS, NCT03994328: An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD

Completed
N/A
1235
Europe
Zambon SpA, Iqvia Pty Ltd
Parkinson's Disease
12/23
12/23
NCT05225324: A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

Recruiting
N/A
600
RoW
Equfina 50 mg
Eisai Korea Inc.
Parkinson Disease
12/25
12/25

Download Options